Original Article

Annals of Hematology

, Volume 94, Issue 2, pp 289-296

First online:

Myeloablative unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: comparison with other graft sources from related and unrelated donors

  • Takaaki KonumaAffiliated withDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo Email author 
  • , Seiko KatoAffiliated withDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo
  • , Jun OoiAffiliated withDepartment of Hematology/Oncology, Teikyo University School of Medicine
  • , Maki Oiwa-MonnaAffiliated withDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo
  • , Arinobu TojoAffiliated withDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo
  • , Satoshi TakahashiAffiliated withDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) is a distinct clinical entity among ALL and is associated with adverse outcomes and higher rates of relapse when conventional chemotherapy is used alone. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for patients with Ph+ALL, the impact of graft sources, particularly cord blood transplantation (CBT), on allo-HSCT for patients with Ph+ALL has yet to be clarified. We retrospectively compared clinical outcomes after unrelated CBT (n = 20), unrelated bone marrow transplantation (n = 7), and related bone marrow and peripheral blood stem cell transplantations (n = 13) following myeloablative conditioning in 40 patients with Ph+ALL. Although graft source had no significant impact on survival or relapse, disease status at transplantation did significantly affect outcomes. These data suggest that unrelated CBT is feasible and should be considered early in the course of patients with Ph+ALL when HLA-compatible related and unrelated donors are not available.

Keywords

Philadelphia chromosome Acute lymphoblastic leukemia Cord blood transplantation Bone marrow transplantation Peripheral blood stem cell transplantation Myeloablative conditioning